339 related articles for article (PubMed ID: 30253174)
1. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Evaluation of
Zhou X; Boellaard R; Ishiwata K; Sakata M; Dierckx RAJO; de Jong JR; Nishiyama S; Ohba H; Tsukada H; de Vries EFJ; Elsinga PH
J Nucl Med; 2017 May; 58(5):762-767. PubMed ID: 28062599
[No Abstract] [Full Text] [Related]
3. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
[TBL] [Abstract][Full Text] [Related]
4. Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys.
Barret O; Hannestad J; Alagille D; Vala C; Tavares A; Papin C; Morley T; Fowles K; Lee H; Seibyl J; Tytgat D; Laruelle M; Tamagnan G
J Nucl Med; 2014 Oct; 55(10):1712-8. PubMed ID: 25082853
[TBL] [Abstract][Full Text] [Related]
5. Initial Evaluation of an Adenosine A
Sakata M; Ishibashi K; Imai M; Wagatsuma K; Ishii K; Zhou X; de Vries EFJ; Elsinga PH; Ishiwata K; Toyohara J
J Nucl Med; 2017 Sep; 58(9):1464-1470. PubMed ID: 28280214
[No Abstract] [Full Text] [Related]
6. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients.
Mishina M; Ishiwata K; Naganawa M; Kimura Y; Kitamura S; Suzuki M; Hashimoto M; Ishibashi K; Oda K; Sakata M; Hamamoto M; Kobayashi S; Katayama Y; Ishii K
PLoS One; 2011 Feb; 6(2):e17338. PubMed ID: 21386999
[TBL] [Abstract][Full Text] [Related]
7. The role of istradefylline in the Parkinson's disease armamentarium.
Müller T
Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
[TBL] [Abstract][Full Text] [Related]
9. Istradefylline - a first generation adenosine A
Jenner P; Mori A; Aradi SD; Hauser RA
Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
[No Abstract] [Full Text] [Related]
10. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.
Perez-Lloret S; Merello M
Expert Opin Pharmacother; 2014 Jun; 15(8):1097-107. PubMed ID: 24673462
[TBL] [Abstract][Full Text] [Related]
11. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
Jenner P
Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Tao Y; Liang G
Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
[TBL] [Abstract][Full Text] [Related]
13. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
14. Istradefylline for the treatment of Parkinson's disease.
Park A; Stacy M
Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371
[TBL] [Abstract][Full Text] [Related]
15. Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease.
Waggan I; Rissanen E; Tuisku J; Matilainen M; Helin S; Parkkola R; Rinne JO; Airas L
Parkinsonism Relat Disord; 2021 May; 86():40-44. PubMed ID: 33831661
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
Mizuno Y; Kondo T;
Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
[TBL] [Abstract][Full Text] [Related]
17. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
[TBL] [Abstract][Full Text] [Related]
18. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
[TBL] [Abstract][Full Text] [Related]
19. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
[TBL] [Abstract][Full Text] [Related]
20. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
Chen W; Wang H; Wei H; Gu S; Wei H
J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
